Feature | May 02, 2014

Medtronic Reveals Positive Outcomes for CoreValve Patients Treated Via Alternative Access Routes

AATS late-breaking data show strong clinical results in complex patient population

May 2, 2014 — Medtronic Inc. revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve system via alternative access approaches. The data were unveiled during a late-breaking clinical session at the 94th American Association for Thoracic Surgery (AATS) annual meeting.

The study evaluated 150 patients from the CoreValve U.S. pivotal trial (23 percent of the extreme risk patient group) who were not suitable for traditional transcatheter aortic valve replacement (TAVR) through the femoral artery, and therefore were treated via subclavian or direct aortic approaches. These patients were more ill and frail than patients treated transfemorally, with higher rates of peripheral vascular disease (61.3 percent of alternate access patients versus 35.2 percent of transfemoral patients, p=0.001). These patients also had significant rates of severe lung disease (39.3 percent of alternate access patients versus 23.5 percent of transfemoral patients, p<0.001) and home oxygen therapy (44.0 percent of alternate access patients versus 29.9 percent of transfemoral patients, p=0.002).

The rate of all-cause mortality or major stroke for these patients was 39.4 percent at 12 months (compared to 26 percent in patients treated transfemorally), an acceptable rate given the higher risk nature of these patients. Rates of moderate or severe aortic regurgitation were low (2.4 percent at one year) and 85.7 percent of these patients improved at one year.

Upon the completion of the extreme risk study, 339 additional patients were treated via a subclavian or direct aortic approach in the continued access study. The mortality rate in the pivotal alternate access patients was 11.3 percent, and in the continued access study this rate improved to 9.5 percent (both at 30 days).

Also in the continued access study compared to the pivotal trial, rates of major stroke at 30 days (3 percent vs. 7.5 percent, p=0.03) and major vascular complications (4.2 percent vs. 8.7 percent, p=0.04) were significantly reduced.

“The data presented demonstrate that multiple implant approaches with the CoreValve system provide positive alternatives for very sick patients who have no other options. These data show that more patients can safely and successfully be treated,” said Michael Reardon, M.D., professor of cardiothoracic surgery at the Methodist DeBakey Heart and Vascular Center in Houston.

The CoreValve system was designed specifically to serve a broad range of TAVR patients. The device has a small 18 French profile for all valve sizes, which minimizes trauma at implant and allows physicians to treat patients with small or calcified vasculature. Its nitinol frame is designed to prevent unwanted leakage and optimize blood flow. In addition, the CoreValve system is available in the broadest range of sizes available, so patients who have smaller, larger or in-between sizes can be accommodated.

The Medtronic CoreValve U.S. pivotal trial’s extreme risk study evaluated the self-expanding device in patients who were considered too ill or frail to have their aortic valves replaced through traditional open-heart surgery. In the rigorous study, all patients were monitored by independent core labs and evaluated against a pre-approved performance goal. Physician “heart teams” were comprised of leading cardiac surgeons and interventional cardiologists in accordance with the U.S. Food and Drug Administration (FDA)-approved protocol.

For more information: www.medtronic.com

Related Content

aortic valve reconstruction, surgery, PinnacleHealth, Pennsylvania
News | Cardiovascular Surgery| May 04, 2016
Three PinnacleHealth patients recently underwent a new procedure for aortic valve reconstruction using the patients'...
Feature | Business| April 28, 2016 | Dave Fornell
 
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
TAVR, Sapien 3, ACC.16
Feature | Heart Valve Repair| April 19, 2016 | Michael J. Rinaldi, M.D., FACC, FSCAI
The continuation of positive clinical trial data for transcatheter aortic valve repair (TAVR), showing it is equal to
Sapien III, Sapien 3, PARTNER II

The Sapien 3 valve has a skirt that has helped significantly reduce paravalvular leaks, which were an issue with earlier generation Sapien devices. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Intermediate-risk patients who received transcatheter aortic valve replacement (TAVR) with the lates
TAVR runoff image

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve repl
TAVR, Sapien 3, ACC.16

Implantation of an Edwards Lifesciences Sapien valve under angiography during the balloon inflation to expand the valve into the aortic annulus. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 —The more frequently a hospital performs a transcatheter aortic valve replacement (TAVR) the better pa
Sponsored Content | Videos | Heart Valve Repair| April 15, 2016
Chandan Devireddy, M.D., assistant professor of medicine at Emory Healthcare in Atlanta and an investigator in the PA
Sponsored Content | Videos | Heart Valve Repair| April 15, 2016
John Carroll, M.D., professor of medicine at the University of Colorado School of Medicine, and director of intervent
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart| April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
Overlay Init